Michael Joseph Boyer

机构：Chris O’Brien Lifehouse · ORCID：0000-0002-0452-2987

发表论文 609 篇 · 总被引 52255 次 · h-index 80

代表论文

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2025 · Clinical Cancer Research · 被引 27)
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study (2025 · Journal of Thoracic Oncology · 被引 18)
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy (2025 · Proceedings of the National Academy of Sciences · 被引 5)
2757O Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study (2025 · Annals of Oncology · 被引 4)
Impact of COVID-19 on lung cancer care in New South Wales, Australia: real-world data from the EnRICH Program (2024 · Public Health Research & Practice · 被引 2)
GDF15 biomarker performance in older patients with advanced non-small cell lung cancer (2026 · Journal of Geriatric Oncology)